Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Business Update
Neumora Therapeutics reported a net loss of $34.4 million for the third quarter of 2026, an improvement from the $56.8 million loss in the same period last year, driven by a 42% reduction in operating expenses. As of September 30, 2026, the company held $85.7 million in cash and cash equivalents, down from $182.5 million at the end of 2025. Management noted the need for additional funding and is evaluating options to reach future value inflection points, while declining to provide updated financial runway guidance. Pipeline progress includes the FDA submission of an Investigational New Drug (IND) application for NMRA-215, a brain-penetrant NLRP3 inhibitor for obesity and cardiometabolic disease, and positive Phase 1b safety data for NMRA-511.